Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875 Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when Guggenheim reaffirmed its Buy rating with a price target of $875. The analyst noted that there was strong demand for tirzepatide in the treatment of diabetes and obesity and that the impending launch of orforglipron w ...

This is why investors looking at Oracle might want to consider a couple of alternatives instead. There are two companies, in particular, that have performance potential that could help them grow faster than Oracle and even surpass Oracle's $801 billion market capitalization by 2030.Oracle's excessive dependence on a few massive contracts, such as its $300 billion deal with OpenAI, also exposes it to a high degree of counterparty risk. If OpenAI changes architectures or pivots away from Oracle Cloud, it coul ...

Core Insights - Eli Lilly's share prices experienced significant growth in 2023 and 2024 due to excitement over GLP-1 diabetes and weight loss therapies, but have since stabilized between $700 and $900 since mid-2024 [2][9] - Valuation concerns, with a forward P/E ratio of around 27, have contributed to the stock's performance, especially when compared to Novo Nordisk's P/E of 14 [3] - Despite current valuation concerns, there is potential for the stock to catch up over the next five years [4] Revenue and Growth Drivers - Lilly's GLP-1 medication, tirzepatide, has been a key revenue driver, generating $5.3 billion in 2023 and projected to reach $16.5 billion in 2024 [6] - Sales for tirzepatide in the first half of 2025 totaled $14.7 billion, with forecasts predicting annual sales to exceed $62 billion in five years [7] - The company is also developing orforglipron, a promising obesity treatment, expected to generate $12.7 billion in annual sales by 2030 [8] Future Outlook - The stock price has remained stable, but sales from diabetes and obesity treatments are anticipated to grow rapidly [9] - While the premium valuation may decrease, further earnings growth could lead to substantial returns over the next five years [9]

Key Points Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and kidneys. Despite a high stock price, Lilly's strong returns and cash-flow generation demonstrate it's worth paying up for. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for ...

The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.Over the past five years, Eli Lilly (LLY 1.43%) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success.But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through ...

9月25日，据美国临床试验登记库显示，礼来撤回了ActRIIA/B单抗bimagrumab与司美格鲁肽核心成分tirzepatide联用治疗2型糖尿病患者的IIb期 临床试验，理由是"战略业务原因"。 这项试验原计划为180名既往超重或肥胖并伴有糖尿病的受试者随机给予bimagrumab、tirzepatide或二者联用，监测70周的体重下降及脂肪/肌肉分 布，试验时间自2024年10月21日起、预计2027年1月结束。礼来强调，对所有项目进行例行评估以优化资源，并未透露试验终止的具体原因，外界 普遍解读为公司需要集中资源推进更具前景的肥胖适应症研究。 这一决定并不意味着礼来放弃bimagrumab赛道。公司仍在开展一项针对非糖尿病肥胖成人的II期试验，该试验同样评估bimagrumab与tirzepatide的 联合效果，公司发言人称结果将于2026年读出。 从时间上看，与原计划2027年结束的糖尿病试验相比，肥胖适应症读数提前一年，礼来把精力投向更有望率先获批的肥胖领域。 "高质量减重"依旧重要 bimagrumab由VersanisBio开发，可阻断ActivinⅡ型受体（ActRII），从而抑制肌肉降 ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

Core Viewpoint - Veru Inc. has received regulatory clarity from the FDA regarding enobosarm, a selective androgen receptor modulator, as a muscle preservation drug candidate in combination with GLP-1 RA for obesity treatment, allowing incremental weight loss as an acceptable primary endpoint for approval [2][3][5]. Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and inflammatory diseases, with enobosarm and sabizabulin as key drug candidates [9]. FDA Meeting Highlights - The FDA has indicated that incremental weight loss with enobosarm added to GLP-1 RA treatment is an acceptable primary endpoint for approval [2]. - Enobosarm 3mg has been confirmed as an acceptable dosage for future clinical development [2]. - The FDA has encouraged the expansion of the enobosarm development program to include younger populations with obesity [2]. Clinical Development Program - The Phase 2b PLATEAU clinical study will evaluate the effect of enobosarm 3mg on total body weight, physical function, and safety in approximately 180 older and younger patients initiating tirzepatide treatment for weight reduction [6][8]. - The primary efficacy endpoint is the percent change from baseline in total body weight at 72 weeks, with key secondary endpoints including total fat mass, total lean mass, and physical function [7]. Phase 2b QUALITY Study Insights - The Phase 2b QUALITY study demonstrated that enobosarm treatment preserved lean mass and improved physical function while leading to greater fat loss during the 16-week active weight loss period [3][10]. - Enobosarm monotherapy was able to prevent weight regain by 46% after discontinuation of semaglutide, resulting in greater fat loss compared to the placebo group [3]. Weight Loss Plateau Context - The weight loss plateau occurs when patients on GLP-1 RA stop losing weight; approximately 88% of patients in the SURMOUNT-1 study reached this plateau by 72 weeks [4]. - Combining tirzepatide with enobosarm is expected to lead to additional fat loss by preserving muscle and physical function, particularly in older patients [4].

Group 1 - Eli Lilly and Company (NYSE: LLY) is identified as a high growth mega cap stock suitable for long-term investment over the next three years, with a recent investment by eCIO Inc. valued at approximately $732,000 [1] - The company is focusing on the obesity and type 2 diabetes treatment markets, with its tirzepatide franchise capturing the GLP-1 market and the experimental drug orforglipron showing greater effectiveness than the competitor's Rybelsus [2] - Eli Lilly's 3-year and 5-year returns have significantly outperformed the market, with returns of 78.37% and 332.72% respectively, indicating strong market standing and growth potential in the oral GLP-1 segment expected to accelerate from 2026 [3] Group 2 - Eli Lilly and Company, founded in 1876 and based in Indiana, specializes in human pharmaceuticals and is committed to improving global health [4]

Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s LLY tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.DataCompared with tirzepatide, Wegovy showed a significant 57% greater risk reduct ...